Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 137

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 137
---
 action or law;

| • |     | the completion of the Divestiture has not occurred by 11:59 p.m., Pacific time, on the Termination Date, except                                                                                                                                          
 (1) if on the Termination Date the only conditions to the completion of the Divestiture that have not been satisfied or validly waived relate to the failure to obtain consents or approvals under certain regulatory laws applicable to the             
 Divestiture or any restraints having been enacted, entered into, enforced or applied to the Divestiture that prevent or materially impair the completion of the Divestiture, but all other conditions to the Divestiture as set forth in the Divestiture 
 Agreement have been satisfied or validly waived, the Termination Date will automatically be extended to September 30, 2025, and (2) the right to terminate the Divestiture Agreement pursuant to this provision will not be available to either          
 Kaken or Aadi if the other party has the right to terminate the Divestiture Agreement pursuant to certain termination provisions of the Divestiture Agreement, or such party’s action or failure to act (which action or failure to act constitutes      
 a breach by such party of the Divestiture Agreement) has been the primary cause of, or primarily resulted in the failure of the completion of the Divestiture to have occurred prior to the Termination Date, including by resulting in a failure of any 
 condition to the Divestiture set forth in the Divestiture Agreement; or                                                                                                                                                                                  |

| • |     | Aadi stockholders do not approve the Divestiture Agreement and the Divestiture at the Special Meeting, except                                                                                                                                      
 that a party may not terminate the Divestiture Agreement pursuant to this provision if such party’s action or failure to act (which action or failure to act constitutes a breach by such party of the Divestiture Agreement) has been the primary 
 cause of, or primarily resulted in, the failure to obtain the approval of Aadi stockholders at the Special Meeting;                                                                                                                                |

| • |     | by Kaken if: |

| • |     | subject to a 20-day cure period, Aadi has breached or failed to perform                                                    
 in any material respect any of its representations, warranties, covenants or other agreements contained in the Divestiture |

- 92 -

| Agreement such that the related closing condition would not be satisfied, unless Kaken is in breach in any material respect of any of its representations, warranties, covenants